ATTENTION ⚠️
In Observance of U.S. Holiday, Memoria Day, Agilent Cross Lab/ iLab Operations Software Support Help Desk will be closed during Canada and U.S. hours on Monday May 29th, 2023. We will resume regular Canada and U.S. support hours on Tuesday May 30th, 2023. EU and APAC Support will remain open during this time. For urgent matters, please add "Urgent" to the ticket/ email subject or press "1", when prompted, to escalate a call on the iLab Support phone and we will prioritize those requests first.
The Containment Level 3 (CL3) Platform has three independent research pods that meet the highest safety standards defined by Canadian Biosafety Standards and Guidelines (PHAC). The facility is available to RI-MUHC researchers, affiliated collaborators and external researchers whose work requires a facility where properly trained users can manipulate various pathogenic organisms (Mycobacterium tuberculosis, SARS-CoV-2). Users of the CL3 Platform must follow the established Standard Operating Procedures (SOPs), as defined in the platform’s SOP manual.
POD1 CL3 facility: Two laboratories (Mycobacterium tuberculosis and SARS-CoV-2) and an animal holding room.
POD 2 CL3 facility: One laboratory (SARS-CoV-2) and an animal holding room
POD3 CL2+ facility: Two laboratories (CL2+ pathogens)
The RI MUHC CL3 Technology Platform must follow strict adherence to procedure, once a set of investigations is approved, the facility manager will oversee training and provide both guidance to researchers and monitoring of experiments.
For further information on the RI MUHC CL3 TB Platform, please contact Fiona McIntosh, Platform manager, at: 514-934-1934 Ext. 44619
For all new projects requiring use of the CL3 Platform facilities, investigators must complete the Application to Use Biohazardous Materials form and submit this document to Environmental Health (EHS) and Safety via email (ri.ehs@muhc.mcgill.ca) for review and approval. EHS will determine if the project requires access to the CL3 Platform. The CL3 Platform will grant access based on space and resources availability. Appropriate training will be provided by the assigned POD supervisor. Note: Due to this reorganization, current and past users may need to amend their Biohazardous Materials form with updated protocols. They may also be required to take “refresher” training to ensure SOPs used in the Platform are of high standard and are consistent with PHAC guidelines.
Director:
Dr. Marcel A. BehrResearch Insitute of the McGill University Health Centre1001 Blvd. Decarie, Room EM3-3212Montreal QC, H4A 3J1
Phone: 514 934-1934 (42815)
email: marcel.behr@mcgill.ca
website:
McGill International TB Centre
Manager:
Fiona McIntosh
phone: 514-934-1934 Ext.44619
Supervisors:
POD1 (TB/SARS-CoV-2-CL3): Andréanne Lupien
POD2 (SARS-CoV-2-CL3):Marianna Orlova
POD3 (CL2+): Marianna Orlova
Hours
|
Location |
Always open | 1001 Blvd. Decarie ES2-6000Montreal QC H4A 3J1 |
Containment Level 3 at the MUHC Research Institute
RIMUHC Technology Platforms website
Canadian Biosafety Standards and Guidelines